{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"3.8","upperLimit":"NA","value":"9.2"},{"comment":"Not estimable due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"24.7","upperLimit":"NA","value":"30.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"95"}],"units":"Participants"}],"description":"DOR was defined as the time from the date that a confirmed response (CR or PR) was first observed to the date of first documented disease progression or death, whichever occurred first. For participants in the monotherapy arm who crossed over to combination therapy, disease assessments after crossover were not included in the DOR calculation. Median DOR was estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Obinutuzumab 1000 milligrams (mg) intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6; and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.","id":"OG000","title":"Obinutuzumab"},{"description":"Zanubrutinib 160 mg twice a day orally with or without food and obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6, and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.","id":"OG001","title":"Zanubrutinib + Obinutuzumab"}],"paramType":"MEDIAN","populationDescription":"The ITT analysis set for this endpoint only included participants with a confirmed response (CR or PR) before disease progression per investigator assessment.","reportingStatus":"POSTED","timeFrame":"From first dose to primary analysis data cutoff (08OCT2021) start of a new anticancer therapy, or the crossover date, whichever came first. Median follow-up was 12.45 months.","title":"Duration of Response (DOR) as Determined by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Months"}